| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651066 | American Heart Journal | 2018 | 28 Pages |
Abstract
Based on a large UK cohort in routine clinical practice, adding a GLP-1RA to insulin therapy is associated with a reduction in risk of composite CV events and all-cause mortality but a nonsignificant higher risk of hospitalization for heart failure in overweight patients with T2D.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Uchenna MD, Jil BSc, PhD, Richard MD, PhD, Iskandar Idris,